Vasudevan, Sridhar - University of Oxford - Department of Pharmacology

个人简介

Sri’s long-standing interest in the development of drugs and small molecule tools evolved from his DPhil studies (2005-2008) on the Ca2+ signalling second messenger nicotinic acid adenine dinucleotide phosphate (NAADP) physiology at a time when suitable small-molecule tools were not available. Sri was then awarded a prestigious BBSRC-RSE Enterprise fellowship in 2009 and in the Churchill lab, he was involved in a number of successful drug discovery ventures on signalling targets including IMPase, GP-VI, HIF and novel anti histamines. In 2012, Sri obtained a departmental lectureship and started working on novel small molecule inhibitors in circadian rhythm related signalling. Sri uses a range of drug development techniques such as virtual screening and drug repurposing and has seen molecules into clinical evaluation. In 2015 he was appointed a Drug Discovery Research Fellow and a BBSRC-new investigator.

研究领域

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Our research interests are to develop new chemical tools and drugs with which to probe cell-signalling mechanisms and physiology. We use a broad range of techniques ranging from traditional biochemistry, computer-based screening and phenotypic screens. Drug repurposing is often a favourite pastime for members of the lab. Some of our current interests include: 1) Identifying novel small molecular modulators of circadian rhythms: Circadian rhythms are ubiquitous 24-h rhythms in behaviour and physiology, regulated by a molecular clock. Our phenotypic screens have identified a range of novel signalling targets through which drugs can modulate the clock and we are evaluating these in cellular and animal models with a view to translate to clinical application in collaboration with Foster Lab. 2) Investigating the role of calcium signalling second messengers in circadian rhythms and vice versa. 3) Understanding signalling mechanisms in bipolar disease: Bipolar disease is a complex psychiatric illness for which the underlying pathophysiology is poorly understood. In collaboration with Churchill lab our work identified the IMPase inhibitor ebselen as a potent lithium mimetic that acts on the inositol signalling axis. Our current studies use patient-based fibroblasts to further study altered signalling in bipolar disease. 4) Developing transcription factor modulators: We have used computer-based screens to indentify molecules that act as transcription factor modulators and are currently evaluating a range of these in cellular models.